LLY Eli Lilly and Company

81.73
-0.79  -1%
Previous Close 82.52
Open 82.64
Price To book 6.38
Market Cap 89983826393
Shares 1,100,988,944
Volume 2,258,435
Short Ratio 3.58
Av. Daily Volume 3,577,575

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released May 12, 2017 - primary endpoints hit in all trials. BLA filing due 2H 2017.
Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN
Migraine prevention
Phase 3 data released August 4, 2017 - endpoints met. NDA filing due 2H 2018.
Lasmiditan - SPARTAN
Migraine
Phase 3 trial to be initiated in 2017.
Ultra rapid insulin
Diabetes
Phase 3 ongoing.
Tanezumab
Chronic low back pain
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 ongoing.
Tanezumab
Osteoarthritis
Phase 3 initiated August 2016. Announced in January 31 earnings call that trial has been terminated - see transcript link here for details.
Solanezumab
Prodromal Alzheimer's disease
Phase 3 ongoing.
Solanezumab
Preclinical Alzheimer's disease
Phase 3 PFS data released May 31, 2017 - primary endpoint met. Final OS results are currently expected in mid-2018.
Ramucirumab
Second-line bladder cancer
Phase 3 initial PFS data met primary endpoint.
Ramucirumab - RAINFALL
First-line gastric cancer
Phase 3 ongoing. Data due 2017 (internal readout).
Flortaucipir F 18 (Tau imaging agent)
Alzheimer's disease
Phase 3 initiated 1Q 2017.
Empagliflozin
Heart failure with preserved ejection fraction (HFpEF)
Phase 3 trial to be initiated in 2018.
Baricitinib
Psoriatic Arthritis
Phase 3 initiated 1Q 2017.
Empagliflozin
Heart failure with reduced ejection fraction (HFrEF)
Phase 3 data due 2019.
AZD3293
Early Alzheimer's disease
Phase 3 interim analysis April 24, 2017 met primary endpoint with regulatory filings due 3Q 2017.
Abemaciclib - MONARCH 3
HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)
Phase 3 data due late 2017.
Alimta + Keytruda (MK-3475-189/KEYNOTE-189)
First-Line Non-Squamous Non-Small Cell Lung Cancer
Phase 3 data released March 20, 2017 - PFS primary endpoint met. Noted July 10, 2017 PDUFA under priority review. No exact data released. Assume 6-month review rendering a PDUFA date on or around January 10, 2018.
Abemaciclib - MONARCH 1 and 2
Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer
Phase 3 ongoing. Data due 2017 (internal readout).
Abemaciclib - JUNIPER
Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)
Announced January 19 2016 that NDA Filing had been submitted. Three month delay announced January 13, 2017. CRL received April 14, 2017. Noted August 30, 2017 that NDA will be resubmitted before the end of January 2018.
Baricitinib
Rheumatoid arthritis
BLA filing due 1H 2017.
Taltz
Psoriatic Arthritis

Latest News

  1. [$$] 4 Buys in a Watchful Market
  2. Eli Lilly Still Looking for Lower Prices
  3. Why Amgen, Lilly, J&J Are Interested In These Small Biotechs
  4. Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study
  5. Why New Generic Products Could Boost TEVA’s Revenue Growth
  6. Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO
  7. Eli Lilly & Co. : LLY-US: Dividend Analysis : August 15th, 2017 (record date) : By the numbers : September 14, 2017
  8. Lilly/Incyte pill beats placebo in mid-stage eczema trial
  9. Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
  10. Astra's Farxiga results may open up type 1 diabetes opportunity
  11. Is Lilly Headed for the Valley?
  12. Drug Companies Tie Costs to Outcomes
  13. Eli Lilly & Co. – Value Analysis (NYSE:LLY) : September 12, 2017
  14. Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control
  15. Array BioPharma And Others Shine At The ESMO 2017 Congress
  16. AbbVie says deaths in arthritis trial not linked to drug
  17. Eli Lilly & Co. breached its 50 day moving average in a Bullish Manner : LLY-US : September 11, 2017
  18. Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress
  19. Corporate News Blog - Eli Lilly's Galcanezumab Treatment Shows Positive Safety Results in the 12-Month Phase-3 Study

SEC Filings

  1. 8-K - Current report 171059789
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17988616
  3. 8-K - Current report 17979263
  4. 11-K - Annual report of employee stock purchase, savings and similar plans 17930276
  5. 8-K/A [Amend] - Current report 17922580
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  7. 8-K - Current report 17883175
  8. SD - 17876416
  9. 8-K - Current report 17817954
  10. 424B2 - Prospectus [Rule 424(b)(2)] 17817285